Skip to content
The Nexus
DossierENTITY

epitalon

Coverage of epitalon in the Nexus archive.

Earliest in view: Jul 24 · 10:05 UTCMost recent: Jul 24 · 10:05 UTC
Co-mentioned in this coverage
FDAorganization1Robert F. Kennedy Jr.person1BPC-157topic1TB-500topic1Peptide Industrytopic1Telehealth companiesorganization1
Recent coverage
  • HEALTHJul 24 · 10:05 UTCBUSINESS INSIDER
    Inside the unconventional FDA panel that could reshape the peptide industry

    An FDA advisory panel led by Robert F. Kennedy Jr. is reviewing seven banned therapeutic peptides, including BPC-157, TB-500, and epitalon, amid concerns over safety and efficacy. The two-day meeting (July 23-24) includes panelists with ties to peptide research, sales, or prescription, marking an unconventional approach to regulatory evaluation.

epitalon · Dossier · The Nexus